South Korea
The success of AimedBio’s IPO may indicate investors are returning to the South Korean biopharma sector amid a series of large global out-licensing deals by domestic ventures and the strong performance of some recent biotech debutants on Kosdaq.
Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.
Korean biopharma firms are bracing for the impending US tariffs on pharmaceuticals and taking different approaches to tackle the situation.
Scrip brings you its quarterly roundup of earnings and other key developments in the Korean pharma sector including the acquisition of Taxotere by Boryung and the progress of Hanmi’s obesity contender.
South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.
Alteogen's preparations to move its stock listing, ABL Bio's injection of funds into its US subsidiary to progress clinical trials and Ensol's plans for a Phase III trial of its osteoarthritis contender are among key recent developments in Korean biotech.
Hanmi is planning to file for Korean approval of the country's first homegrown obesity contender efpeglenatide by year-end, following positive topline Phase III data for the Sanofi U-turned asset.
At recent conferences in Seoul, participants discussed various hurdles for growth in the Korean biotech ecosystem and potential opportunities such as the ongoing collaborations between Korea and Japan.
KIMCo CEO talks to Scrip about how the Korean open innovation platform and life science accelerator and its member firms are notching up efforts to nurture Korean bioventures through the country’s first coalition fund.
Yuhan's R&D president talks to Scrip about the leading Korean pharma firm’s open innovation strategy with Korean bioventures, as well as other strategies crucial for the company to transform into a major global player.
Stonebridge Ventures’ managing director Hyun-Ki Kim talks to Scrip on factors constraining the recovery of VC funding in Korean bioventures and its investment considerations, strategies and priorities.
Scrip takes a look at the "burgeoning" South Korea radiopharmaceuticals sector, where a handful of pioneering domestic companies are racing to advance their pipelines, with prostate cancer a strong early focus.
Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.
Yuhan and GC Biopharma’s performances stood out among South Korean companies reporting Q2 results, boosted by license income, strong global growth and exports, while many others reported generally weaker figures.
Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.
While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.
Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges